By admin | March 19, 2010
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500 patients recruited into the pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS)…
By admin | March 18, 2010
The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease). “Aestus is a key, strategic drug discovery partner in the effort to identify potential therapeutics for ALS…
By admin | March 17, 2010
Preserving a shortened version of the SMN protein rescued SMN-deficient cells, opening the door to a possible new therapeutic strategy
By admin | March 17, 2010
Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr…
By admin | March 16, 2010
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients – a fatal and most common form of muscular dystrophy in children. The chemical, which Medical School scientists have termed a “molecular band-aid,” seeks out tiny cuts in diseased heart muscle…
By admin | March 14, 2010
An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign…
By admin | March 11, 2010
What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign. The conference will be an opportunity for families to learn more about fighting for better muscle disease services in their region and to find out how local campaigning can make a real difference…
Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis…
‘Muscle Gene Therapy’ brings together the latest research in this promising field.
ALS TDI’s first-quarter 2010 research update can be summed up with one word: momentum.
